EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects

Hu Zhao, Senxuan Zhang, Fang Wang, Peirong Yu, Jin Li, Lina Jia, Pengfei He, Run Liu, Jian Zhang, KeXin Wang, Rui Han, Hui Huangfu

Frontiers in Immunology · 21.05.2026 · 17

DOI: 10.3389/fimmu.2026.1828131 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Frontiers in Immunology, online erschienen am 21.05.2026. Verfasst von Hu Zhao und 11 weiteren Autor:innen. Beteiligte Einrichtung: Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University, Taiyuan, China. Hauptthemen laut MEDLINE: Immunoconjugates, Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 136 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a highly aggressive disease entity with poor prognosis. Current systemic treatment regimens, including chemotherapy, targeted therapy, and immune checkpoint inhibitors, provide only limited and often short-lived clinical benefits. As an innovative therapeutic approach, antibody-drug conjugates (ADCs) combine the tumor-targeting specificity of monoclonal antibodies with the potent cytotoxicity of the conjugated payload, enabling selective delivery of highly active drugs to cancer cells. Given the urgent need to improve clinical outcomes for R/M HNSCC, ADCs have emerged as a highly promising therapeutic strategy and are increasingly becoming the focus of translational research and clinical trials, with encouraging signals observed in both early and late-stage trials. This review comprehensively outlines the biological principles, antigen targets, and current clinical development progress of ADCs in treating R/M HNSCC. It begins with a brief explanation of ADC structural principles, followed by a systematic summary of all preclinical and clinical evidence supporting ADC therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunoconjugatesSquamous Cell Carcinoma of Head and NeckHead and Neck NeoplasmsAntineoplastic Agents, ImmunologicalHumansAnimalsNeoplasm Recurrence, LocalMolecular Targeted TherapyNeoplasm Metastasis

Stichwörter der Autor:innen

R/M HNSCCantibody–drug conjugatescancerclinical applicationtargeted therapy

Substanzen

ImmunoconjugatesAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Otorhinolaryngology and Head and Neck Surgery, The First Hospital of Shanxi Medical University, Taiyuan, China.
  • First Clinical Medical College, Shanxi Medical University, Taiyuan, China.

Zitieren

APA

Zhao, H., Zhang, S., Wang, F., Yu, P., Li, J., Jia, L., He, P., Liu, R., Zhang, J., Wang, K., Han, R., & Huangfu, H. (2026). Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1828131

Vancouver

Zhao H, Zhang S, Wang F, Yu P, Li J, Jia L, et al. Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1828131

BibTeX
@article{Zhao2026,
  author = {Zhao, Hu and Zhang, Senxuan and Wang, Fang and Yu, Peirong and Li, Jin and Jia, Lina and He, Pengfei and Liu, Run and Zhang, Jian and Wang, KeXin and Han, Rui and Huangfu, Hui},
  title = {Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects},
  journal = {Frontiers in Immunology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fimmu.2026.1828131}
}
Kostenlos starten →